Maine-Anjou AAV-GN Research Group
@maineanjoureg.bsky.social
The Maine-Anjou Research Group is a multicenter French team focusing on #ANCA associated #vasculitis with #glomerulonephritis. Posts by @benoitbrilland.bsky.social
Empagliflozin in lupus mice. Two studies, opposite results:
🔹 Zhao, ARD 2023 🇨🇳: early use ↓proteinuria, ↓anti-dsDNA, improved podocyte autophagy. doi.org/10.1136/ard-...
🔹 Vilardell-Vilà, KI 2025 🇪🇸: no benefit when started during active nephritis. doi.org/10.1016/j.ki...
🔹 Zhao, ARD 2023 🇨🇳: early use ↓proteinuria, ↓anti-dsDNA, improved podocyte autophagy. doi.org/10.1136/ard-...
🔹 Vilardell-Vilà, KI 2025 🇪🇸: no benefit when started during active nephritis. doi.org/10.1016/j.ki...
November 7, 2025 at 3:10 PM
Empagliflozin in lupus mice. Two studies, opposite results:
🔹 Zhao, ARD 2023 🇨🇳: early use ↓proteinuria, ↓anti-dsDNA, improved podocyte autophagy. doi.org/10.1136/ard-...
🔹 Vilardell-Vilà, KI 2025 🇪🇸: no benefit when started during active nephritis. doi.org/10.1016/j.ki...
🔹 Zhao, ARD 2023 🇨🇳: early use ↓proteinuria, ↓anti-dsDNA, improved podocyte autophagy. doi.org/10.1136/ard-...
🔹 Vilardell-Vilà, KI 2025 🇪🇸: no benefit when started during active nephritis. doi.org/10.1016/j.ki...
We uncovered a powerful type I interferon signature in #ANCA #vasculitis, especially in MPA, tied to kidney prognosis, and close to lupus nephritis. 🚀 This opens exciting perspectives for IFN–targeted therapies in vasculitis. Full results presented at #KidneyWk @asnkidney.bsky.social in a few hours!
November 4, 2025 at 7:21 PM
We uncovered a powerful type I interferon signature in #ANCA #vasculitis, especially in MPA, tied to kidney prognosis, and close to lupus nephritis. 🚀 This opens exciting perspectives for IFN–targeted therapies in vasculitis. Full results presented at #KidneyWk @asnkidney.bsky.social in a few hours!
Groundbreaking work by @tharaux-lenoir-lab.bsky.social: blocking mineralocorticoid receptor signaling in parietal epithelial cells prevents crescentic GN. Shall we stop using methylpred pulses for AAV-GN induction, given their unwanted mineralocorticoid activity? doi.org/10.1016/j.kint.2025.07.037
October 21, 2025 at 2:21 PM
Groundbreaking work by @tharaux-lenoir-lab.bsky.social: blocking mineralocorticoid receptor signaling in parietal epithelial cells prevents crescentic GN. Shall we stop using methylpred pulses for AAV-GN induction, given their unwanted mineralocorticoid activity? doi.org/10.1016/j.kint.2025.07.037
Outstanding review that outlines evolving #ANCA #vasculitis treatments: from B-cell therapies (obinutuzumab, CAR-T) and T-cell therapies (ustekinumab) to new comers (T-cell engagers, alternative-pathway inhibitors, antifibrotics, ANCA–antigen blockers). A must read! www.nature.com/articles/s41...
June 10, 2025 at 6:56 PM
Outstanding review that outlines evolving #ANCA #vasculitis treatments: from B-cell therapies (obinutuzumab, CAR-T) and T-cell therapies (ustekinumab) to new comers (T-cell engagers, alternative-pathway inhibitors, antifibrotics, ANCA–antigen blockers). A must read! www.nature.com/articles/s41...
Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social
April 25, 2025 at 2:06 PM
Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social
Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...
April 1, 2025 at 1:08 PM
Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...
This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️
April 1, 2025 at 12:49 PM
This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️
Last one: IV methylpred in very severe (eGFR<10 ml/min) #ANCA #vasculitis. Retrospective Chinese study, N=106, mostly MPO, high MMF use. IVMP (vs. no): higher dialysis independence (37% vs. 7%) & nearly significant lower mortality (19% vs. 37%, p = .056). bmcnephrol.biomedcentral.com/articles/10....
January 9, 2025 at 3:51 PM
Last one: IV methylpred in very severe (eGFR<10 ml/min) #ANCA #vasculitis. Retrospective Chinese study, N=106, mostly MPO, high MMF use. IVMP (vs. no): higher dialysis independence (37% vs. 7%) & nearly significant lower mortality (19% vs. 37%, p = .056). bmcnephrol.biomedcentral.com/articles/10....
IV methyl pred in severe (sCr > 500 or dialysis) #ANCA #vasculitis (observ.): no benefit for survival or renal recovery at M12. Higher risks of infections & diabetes with IVMP. Lower doses (1.5g total), more severe patients, MPO/PR3 more balanced than ⬇️. bmcnephrol.biomedcentral.com/articles/10....
January 9, 2025 at 3:31 PM
IV methyl pred in severe (sCr > 500 or dialysis) #ANCA #vasculitis (observ.): no benefit for survival or renal recovery at M12. Higher risks of infections & diabetes with IVMP. Lower doses (1.5g total), more severe patients, MPO/PR3 more balanced than ⬇️. bmcnephrol.biomedcentral.com/articles/10....
IV methylpred in "severe" #ANCA #vasculitis (observational study, target trial emulation): 1.0 g/day reduced 48-week mortality without increasing serious infections. 0.5 g/day showed limited effect. Limits: quite small number of subjects (201), mostly MPO. academic.oup.com/rheumatology...
January 9, 2025 at 3:24 PM
IV methylpred in "severe" #ANCA #vasculitis (observational study, target trial emulation): 1.0 g/day reduced 48-week mortality without increasing serious infections. 0.5 g/day showed limited effect. Limits: quite small number of subjects (201), mostly MPO. academic.oup.com/rheumatology...
PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...
January 8, 2025 at 4:31 PM
PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...
66% of #ANCA #vasculitis patients have coronary artery calcification (CAC score>0), indicating high cardiovascular risk, especially in MPO+. Only 25% are on statins. Urgent need for better screening and tailored cardiovascular prevention. rmdopen.bmj.com/content/11/1...
January 7, 2025 at 4:50 PM
66% of #ANCA #vasculitis patients have coronary artery calcification (CAC score>0), indicating high cardiovascular risk, especially in MPO+. Only 25% are on statins. Urgent need for better screening and tailored cardiovascular prevention. rmdopen.bmj.com/content/11/1...
Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...
January 6, 2025 at 3:25 PM
Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...
In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/
December 17, 2024 at 2:29 PM
In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/
First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...
December 12, 2024 at 6:18 PM
First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...
Abatacept RCT vs placebo (on top of oral GC) in relapsing non severe granulomatosis #GPA #vasculitis (ABROGATE study): non superiority of abatacept. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point (and SAEs). Dr. C. Langford #ACR24 acrabstracts.org/abstract/a-r...
December 3, 2024 at 6:48 PM
Abatacept RCT vs placebo (on top of oral GC) in relapsing non severe granulomatosis #GPA #vasculitis (ABROGATE study): non superiority of abatacept. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point (and SAEs). Dr. C. Langford #ACR24 acrabstracts.org/abstract/a-r...
Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
December 2, 2024 at 5:22 PM
Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...
November 26, 2024 at 2:29 PM
Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...